Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease
Bone Marrow Transplant
.
2023 Dec;58(12):1397-1399.
doi: 10.1038/s41409-023-02103-3.
Epub 2023 Sep 5.
Authors
Preeti Prerna M Vaswani
1
2
,
Masahiro Onozawa
3
,
Yuta Hasegawa
1
,
Hiroyuki Ohigashi
1
,
Takahide Ara
1
,
Toshihiro Matsukawa
1
,
Atsushi Yasumoto
1
,
Souichi Shiratori
1
,
Hideki Goto
1
,
Masao Nakagawa
1
,
Kaoru Kahata
1
,
Tomoyuki Endo
1
,
Daigo Hashimoto
1
,
Takanori Teshima
1
Affiliations
1
Department of Hematology, Hokkaido University, Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan.
2
Section of Hematology, Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
3
Department of Hematology, Hokkaido University, Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan.
[email protected]
.
PMID:
37670048
DOI:
10.1038/s41409-023-02103-3
No abstract available
Publication types
Letter
MeSH terms
Adult
Epstein-Barr Virus Infections*
Hematopoietic Stem Cell Transplantation* / adverse effects
Herpesvirus 4, Human
Humans
Incidence
Lymphoproliferative Disorders* / complications
Viremia / etiology